Sweden's Hansa Biopharma Q2 revenue dips

Hansa Biopharma AB

22/07/2026 06:08

    

    Overview
  
Sweden biopharma firm's Q2 revenue declined slightly yr/yr, reflecting a weaker first quarter
Company signed €115 mln out-licensing deal for Idefirix with SERB Pharmaceuticals
Positive European confirmatory trial results support full approval application for Idefirix

    

    Outlook
  
Hansa Biopharma expects to receive an additional €5 mln payment upon EMA filing acceptance for Idefirix
Company says positive PAES trial data supports submission for full EMA marketing authorization for Idefirix

    

    Result Drivers
  
COMMERCIAL EXECUTION - Co said improved commercial execution in Q2 led to a 39% increase over Q1
REGIONAL GROWTH - Continued growth in Spain after reimbursement in Catalonia and strong performance in France; solid demand in Germany, Italy and the UK

    
Company press release: ID:nWkr9dH3zn

    

    Key Details
  

            Metric
          

            Beat/Miss
          

            Actual
          

            Consensus Estimate
          
Q2 Revenue
 
SEK 48.10 mln
 
Q2 Adjusted EPS
 
-SEK 2.56
 
Q2 Net Income
 
-SEK 260.50 mln
 
Q2 Cash & Investments
 
SEK 552.80 mln
 
Q2 EBIT
 
-SEK 174.10 mln
 

    

    Analyst Coverage
  
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Hansa Biopharma AB is SEK75.00, about 124.7% above its July 21 closing price of SEK33.38

    

    Reuters Recommended Reads
  
July 21 - Sweden's Asker Healthcare Q2 profit jumps on increased scale
July 21 - Switzerland's Novartis beats Q2 sales estimates on strong sales across priority brands
July 20 - Scholar Rock says EU opinion on SMA drug may be pushed to later in 2026

    
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)